Eunice L Kwak MD PhD

Oncology•Boston, MA

Physician

Join to View Full Profile

55 Fruit St Yaw 7Hematology/OncologyBoston, MA 02114
Phone+1 617-726-6254
Fax+1 617-724-6919

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1999 - 2003
Duke University School of MedicineClass of 1996

Certifications & Licensure

MA State Medical License 2001 - 2017

Clinical Trials

Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer Start of enrollment: 2007 Nov 01
Completed
Phase 2
Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer Start of enrollment: 2007 Oct 01
Terminated
Phase 1
Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer Start of enrollment: 2007 Nov 01
Completed
Phase 1
A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors Start of enrollment: 2008 Sep 01
Terminated
Phase 1
A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer Start of enrollment: 2009 Aug 01
Completed
Phase 1
Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
Completed
Phase 1
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer Start of enrollment: 2010 Aug 01
Completed
Phase 2
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
ACTIVE_NOT_RECRUITING
PHASE2
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer Start of enrollment: 2011 Dec 01
Completed
Phase 1
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer Start of enrollment: 2013 Jan 01
Completed
Phase 2
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma Start of enrollment: 2013 Apr 01
Completed
Phase 1
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread Start of enrollment: 2014 Mar 12
COMPLETED
PHASE2
Join now to see all

Publications & Presentations

PubMed

10 citations
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S Hong, Lillian L Siu
Oncoimmunology. 2024-01-01
92 citations
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
Patrick Schöffski, Daniel S W Tan, Miguel Martín, María Ochoa-de-Olza, John Sarantopoulos
Journal for Immunotherapy of Cancer. 2022-02-01
2 citations
Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers.
Surendra Pal Chaudhary, Eunice L. Kwak, Katie L. Hwang, Jochen K. Lennerz, Ryan B. Corcoran
The Oncologist. 2020-11-01

Journal Articles

Phase 1 Study of AMG 337, a Highly Selective Small-Molecule MET Inhibitor, in Patients with Advanced Solid Tumors
Eunice L Kwak, Filip Janku, David S Hong, Clinical Cancer Research